Side effects of oral misoprostol for the prevention of postpartum hemorrhage: Results of a community-based randomised controlled trial in rural India

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 22, Issue 1, 2009, Pages 24-28

  Patted, Shobhana S ^a,h   Goudar, Shivaprasad S ^a   Naik, Vijaya A ^a   Bellad, Mrutyunjaya B ^a   Edlavitch, Stanley A ^b   Kodkany, Bhalchandra S ^a   Patel, Ashlesha ^c   Chakraborty, Hrishikesh ^d   Derman, Richard J ^e,f   Geller, Stacie E ^g  

^a JAWAHARLAL NEHRU MEDICAL COLLEGE   (India)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c Jr Hospital of Cook County   (United States)

^d RTI INTERNATIONAL   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f CHRISTIANA CARE HEALTH SYSTEM   (United States)

^g UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^h KLE UNIVERSITY   (India)

Author keywords

Misoprostol; Postpartum hemorrhage; Side effects

Indexed keywords

MISOPROSTOL;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FEVER; HUMAN; INDIA; LABOR STAGE 3; MAJOR CLINICAL STUDY; NAUSEA; POSTPARTUM HEMORRHAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; RURAL AREA; SHIVERING; SINGLE DRUG DOSE; SYMPTOMATOLOGY; VOMITING;

ADMINISTRATION, ORAL; DIARRHEA, INFANTILE; FEMALE; FEVER; HUMANS; INCIDENCE; INDIA; INFANT, NEWBORN; MATERNAL-FETAL EXCHANGE; MISOPROSTOL; NAUSEA; OXYTOCICS; PLACEBOS; POSTPARTUM HEMORRHAGE; PREGNANCY; RESIDENCE CHARACTERISTICS; RURAL POPULATION; SHIVERING; VOMITING;

EID: 61649096129     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.1080/14767050802452309     Document Type: Article

References (20)

1. Sample Registration System, Maternal Mortality in India: 1997-2003. Trends, Causes and Risk Factors, Registrar General, New Delhi, India and Centre for Global Health Research, University of Toronto, Canada.
2. Elbourne DR, Prendiville WJ, Carroli G, Wood J, McDonald S. Prophylactic use of oxytocin in the third stage of labour. Cochrane Database Syst Rev 2001: CD001808.
3. National Neonatology Forum. State of India's Newborns. New Delhi, India; National Neonatology Forum, 2004.
4. Sibley L, Ann Sipe T. What can a meta-analysis tell us about traditional birth attendant training and pregnancy outcomes? Midwifery 2004;20:51-60.
5. Hofmeyr GJ, Nikodem VC, de Jager M, Gelbart BR. A randomised placebo controlled trial of oral misoprostol in the third stage of labour. Br J Obstet Gynaecol 1998;105:971-975.
6. Bamigboye AA, Hofmeyr GJ, Merrell DA. Rectal misoprostol in the prevention of postpartum hemorrhage: A placebo-controlled trial. Am J Obstet Gynecol 1998;179:1043-1046.
7. Bamigboye AA, Merrell DA, Hofmeyr GJ, Mitchell R. Randomized comparison of rectal misoprostol with Syntometrine for management of third stage of labor. Acta Obstet Gynecol Scand 1998;77:178-181.
8. Derman RJ, Kodkany BS, Goudar SS, Geller SE, Naik VA, Bellad M, Patted SS, Patel A, Edlavitch SA, Hartwell T, et al. Oral misoprostol in preventing postpartum haemorrhage in resource-poor communities: A randomised controlled trial. Lancet 2006;368:1248-1253.
9. Walraven G, Blum J, Dampha Y, Sowe M, Morison L, Winikoff B, Sloan N. Misoprostol in the management of the third stage of labour in the home delivery setting in rural Gambia: A randomised controlled trial. BJOG 2005;112: 1277-1283.
10. Lalonde A, Daviss BA, Acosta A, Herschderfer K. Postpartum hemorrhage today: ICM/FIGO initiative 2004-2006. Int J Gynaecol Obstet 2006;94:243-253.
11. Lumbiganon P, Hofmeyr J, Gulmezoglu AM, Pinol A, Villar J. Misoprostol dose-related shivering and pyrexia in the third stage of labour. WHO Collaborative Trial of Misoprostol in the Management of the Third Stage of Labour. Br J Obstet Gynaecol 1999;106:304-308.
12. Hofmeyr GJ, Nikodem VC, de Jager M, Drakely A. Side-effects of oral misoprostol in the third stage of labour - a randomised placebo-controlled trial. S Afr Med J 2001;91:432-435.
13. Lumbiganon P, Villar J, Piaggio G, Gulmezoglu AM, Adetoro L, Carroli G. Side effects of oral misoprostol during the first 24 h after administration in the third stage of labour. BJOG 2002;109:1222-1226.
14. el-Refaey H, O'Brien P, Morafa W, Walder J, Rodeck C. Use of oral misoprostol in the prevention of postpartum haemorrhage. BJOG 1997;104:336-339.
15. Hofmeyr GJ, Walraven G, Gulmezoglu AM, Maholwana B, Alfirevic Z, Villar J. Misoprostol to treat postpartum haemorrhage: A systematic review. Br J Obstet Gynaecol 2005;112:547-553.
16. el-Refaey H, Templeton A. Induction of abortion in the second trimester by a combination of misoprostol and mifepristone: A randomized comparison between two misoprostol regimens. Hum Reprod 1995;10:475-478.
17. Khan RU, El-Refaey H. Pharmacokinetics and adverse-effect profile of rectally administered misoprostol in the third stage of labor. Obstet Gynecol 2003;101:968-974.
18. Abdel-Aleem H, Villar J, Gulmezoglu AM, Mostafa SA, Youssef AA, Shokry M, Watzer B. The pharmacokinetics of the prostaglandin E1 analogue misoprostol in plasma and colostrum after postpartum oral administration. Eur J Obstet Gynecol Reprod Biol 2003;108:25-28.
19. Gulmezoglu AM, Villar J, Ngoc NT, Piaggio G, Carroli G, Adetoro L, Abdel-Aleem H, Cheng L, Hofmeyr G, Lumbiganon P, et al. WHO multicentre randomised trial of misoprostol in the management of the third stage of labour. Lancet 2001;358:689-695.
20. Daisley H, Jr. Maternal mortality following the use of misoprostol. Med Sci Law 2000;40:78-82.